We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies.
Present your Company
The DESERT ANGELS ™ welcomes applications from startup or early stage companies. We evaluate applications on an ongoing basis and meet monthly from September through June.
Present your company
Become a member
As a vibrant, growing organization, the DESERT ANGELS ™ welcomes new members. If you are an accredited investor with a tenacious appetite for helping early-stage companies succeed, we’d love to get to know you better at an upcoming dinner meeting.
It is safe to say that there would have been no Calimmune without the early support of the Desert Angels.
Many members of the DA share our passion and see the potential for gene therapy to transform healthcare and liberate patients from chronic and incurable diseases. Their investments have helped us grow this company to what it is today. We truly hope Calimmune’s work will be life-changing for the people we plan to serve and the investors that supported us.
For some, the words “financial aid” stirs up reminders of grueling applications and the anxiety of coping with skyrocketing college tuition. Phoenix-based CampusLogic aims to chip away at some of those challenges by helping institutions manage and award financial aid to more students, as well as reduce student borrowing by connecting colleges with private grant […]
CampusLogic, the leading student financial services (SFS) platform, today announced $55 million in funding led by JMI Equity, a growth equity firm focused on investing in leading software companies. Founded in 2011, CampusLogic is a market leader in SFS software with nearly 500 higher education customers that serve more than three million students. CampusLogic, which […]
HTG Molecular Diagnostics, Inc.(Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Japan Patent Number 6290202 for “Nuclease Protection Methods for Detection of Nucleotide Variants.” The patented technology involves a nuclease-protection method using wild‑type and variant probes competing for binding to a target nucleic acid molecule, such […]